Ross from Goldman Sachs has the following forecasts on CRISPR Therapeutics between $2023-2027$ at the end of $2022.$

$20232024202520262027$

EPS $12\mathrm{.}3013\mathrm{.}2315\mathrm{.}7113\mathrm{.}5317\mathrm{.}20$

DPS $0\mathrm{.}720\mathrm{.}911\mathrm{.}632\mathrm{.}112\mathrm{.}30$

The long$-$term growth rate in AEG for CRISPR Therapeutics is $7\%$ after $2027.$ However, Ross expects a temporary drop in the long$-$term growth rate for $3$ years to $3\mathrm{.}5\%$ after $2029,$ and then jump back up to $7\%$ in another $4$ years. CRISPR is then expected to sustain at a fixed growth of $7\%$ indefinitely conditional on a $11\mathrm{.}50\%$ cost of equity.

Which of the following is closest to the fair stock price of the stock at the end of $2022?$